Key Takeaways
- FY28 guidance anchored at $400 mn: Management committed to $400 mn organic revenue by FY28 with 38–40% EBITDA margins, implying a 30% CAGR from FY25, and declared it sees no risk to that target.
- FY26 is a deliberate transition year: Revenue will be lumpy, with a tepid H1 and a strong H2 mirroring FY25, as the bulk of growth shifts to commercial sales of DDC products whose timing depends on customer approvals and patent expiries.
- Capacity doubling to capture the GLP wave: Rated capacity is expanding from 4 crore to over 9 crore units by December, funded by a $100 mn capex plan, with customer forecasts extending three years and reservation fees already collected.
- Margins already at steady-state levels: Q4 EBITDA margin hit 43%, and management reiterated a 40% steady-state target, with operating leverage from the DDC mix and a halving of net debt already visible.
- What to watch next quarter: Whether liraglutide launches materialize, the pace of customer approvals in newly opened markets like Canada and Brazil, and any sign that the FY26 H1 tepidness is tracking better or worse than the transition-year script.
The FY28 Ambition and the Transition-Year Bridge
- The $400 mn target: Management guided to $400 mn organic revenue by FY28, with EBITDA in the 38–40% range, implying a 30% revenue CAGR from the FY25 base of ₹1,444.9 crore.
- FY26 as the hinge: FY26 is explicitly framed as a transition year where the revenue mix shifts from MSA-driven work to commercial CSA sales of DDC products. The year will be lumpy: H1 more tepid, H2 stronger, mirroring the pattern seen in FY25.
- Exit run-rate ambition: Management aims for the FY26 exit run-rate to be in the zip code of the FY28 trajectory on an annualized basis, though quarter-on-quarter linearity will not hold. This depends entirely on product and customer approvals.
- FY27 as the steady state: FY27 is expected to deliver solid, consistent quarter-on-quarter growth as it becomes the first full year of semaglutide commercialization across multiple markets and CSA contributions normalize.
- No risk to FY28, per management: When pressed on what could derail the FY28 target, management pointed to market expansion and multiple levers but offered no quantified risk scenarios, stating flatly that it sees no risk to the guidance.
Arun Kumar: "So I strongly believe that we do not see any risk to our FY '28."
DDC: The Engine, the Pipeline, and the Capacity Bet
- DDC is the dominant revenue driver: Drug device combinations will continue to be the significant driver of revenue in FY26 and beyond, and underpin the FY28 outlook. The company has delivered or is executing close to 50 DDC projects across small and large molecules.
- Customer base deepening: The DDC customer count now exceeds 20, including leading innovators, biotechs, and top global generics companies. Total logos across all offerings crossed 70 after 15 new additions in the year.
- Capacity doubling to meet demand: Rated capacity is expanding from 4 crore to a little over 9 crore units as early as December, with new combi lines that can run 100% cartridges or 100% vials. Customers have provided forecasts extending three years, so the ramp is demand-backed.
- Customer onboarding paused for GLPs: Management will not onboard additional DDC customers for GLP-1 products to avoid capacity clashes that could upset existing relationships, though it may add customers around other formats.
- First non-GLP DDC products arriving: The first DDC product approved in the U.S. is a non-GLP peptide (first of its type), and the first approved in Europe is a biologic peptide. Both are attractive but carry smaller volumes than GLPs because their addressable markets differ.
- NBE is a 2028–29 story: The first-in-class NBE product enters clinical production this year, but commercialization is not expected until 2028–29, so the near-term outlook carries no meaningful contribution from it.
Arun Kumar: "So consequently, taking more customers at the cost of upsetting established customer relations is not something any CDMO, for that matter, we would do."
Market Openings and Launch Timelines
- Semaglutide patent expiry unlocks markets in Q4: The largest markets going off-patent include Canada (early January 2026), Brazil, Saudi Arabia, and India, with the bulk of countries opening in March 2026. Commercial supplies would start in Q4 from a freedom-to-operate perspective.
- Liraglutide could launch next quarter: Customers already hold liraglutide approvals, especially for Europe, and the launch depends only on the customers' own ability to go to market. No delay stems from any regulatory observation.
- Teriparatide and other products in FY26: Teriparatide approval is already in place, with launch planned within FY26. Multiple products are moving from MSA to CSA as approvals come in, with no change to that trajectory.
- Site readiness for new markets: OneSource is fully ready for Brazil from a site approval, capability, and capacity standpoint, awaiting only customer approvals. Canada requires no separate Health Canada inspection because the site already holds FDA and European approvals.
- New line addition without re-inspection: A new line being added within the current suite at the existing site is expected to enter the market as soon as it is ready and qualified, based on management's reading of FDA and other agency guidance that no further inspection is needed.
Pricing, Competition, and the Oral vs. Injectable Debate
- Pricing is volume-based and geography-agnostic: The CDMO takes only a small fraction of the in-market price, so pricing is tied to volume with staggered structures and is completely independent of where the customer launches. Management sees no impact from market pricing dynamics on its own pricing.
- Oral GLP-1s seen as a limited threat: Management cited Lilly's own statement that peak oral share will be no more than 25% of the anti-obesity market. The combination of pill burden, pricing, and availability in off-patent markets makes the oral impact more a question of timing than a structural risk to injectables.
- Once-a-month injectables as the next frontier: A once-a-month injectable would be way more attractive than a daily tablet, reinforcing the injectable format's dominance even as innovation evolves.
- Pricing assumptions in the guidance were not disclosed: When an analyst asked whether the $400 mn FY28 target assumes stable pricing per pen in a given market, management declined to answer and cut off the question citing time constraints.
- Contract pricing mechanics also undisclosed: When asked whether take-or-pay contracts carry annual price revision clauses, management deflected, saying there is only so much a CDMO can disclose on that topic.
Neeraj Sharma: "Lilly has very clearly mentioned that they expect the peak share of their oral product to be no more than 25% of the total anti-obesity market."
Financial Position and Capital Allocation
- Debt halved and still falling: Net debt was reduced to ₹470.7 crore after prepaying high-cost debt, cutting interest costs 20% quarter-on-quarter to ₹27.8 crore. A credit rating upgrade has improved access to economical funding.
- Net-debt-free ambition: Management aims to be net debt free within the next 2–3 years and to maintain debt below 1.5x EBITDA over the medium term.
- Capex plan of $100 mn over two years: Investment will continue at roughly $100 mn over the next couple of years, balanced across leverage, internal accruals, and customer participation. Fixed asset turns are expected to remain above 2x.
- Operating leverage already visible: Q4 EBITDA of ₹182.5 crore grew 79% YoY on 22% revenue growth, with the 43% margin reflecting the DDC mix even though most revenue still came from MSAs. Full-year adjusted PAT was ₹93.6 crore excluding one-timers.
- DDC revenue breakdown withheld: Management declined to break out DDC revenue for either the quarter or the full year, describing instead the number and stages of DDC projects.
Operational Resilience and Compliance
- Compliance track record is extensive: The company handled more than 60 regulatory and customer audits during the year, including successful FDA re-inspections at penicillin and general injectable sites, a Health Canada inspection, and approvals from ANVISA and Saudi agencies at the flagship site.
- Compliance risk is acknowledged: Management noted that compliance is an added risk in the CDMO business and that the company is only as good as its next inspection, though it expressed confidence given the group's investment in digitalization and quality standards.
- Integration and leadership build-out: Significant progress was made on integrating systems, processes, and IT to drive customer wallet share and operational synergies. The leadership team and board were both strengthened with new additions.
Arun Kumar: "We all know that we are only as good as our next inspection."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic revenue target | $400 mn | FY28 |
| EBITDA margin target | 38–40% | FY28 |
| Revenue CAGR | 30% | FY25 to FY28 |
| Steady-state EBITDA margin | 40% | Steady state (no date) |
| FY26 revenue pattern | H1 tepid, H2 strong; exit run-rate annualized in zip code of FY28 trajectory | FY26 |
| FY27 growth profile | Solid, consistent QoQ growth; first full year of Sema commercialization | FY27 |
| Rated capacity expansion | From 4 crore to over 9 crore units | By December |
| Capex | ~$100 mn over next couple of years | Next 2 years |
| Net debt target | Net debt free | Next 2–3 years |
| Debt-to-EBITDA ceiling | Below 1.5x | Medium term |
| Fixed asset turns | Above 2x | Ongoing |
| Liraglutide commercial launch | Dependent on customer readiness | As soon as next quarter |
| Teriparatide commercial launch | Approval already in place | Within FY26 |
| First non-GLP DDC product (US) commercialization | First-of-type peptide DDC | FY26 |
| First biologic peptide DDC (Europe) commercialization | Already approved | FY26 |
| NBE commercialization | First-in-class biologic | 2028–29 |
| Semaglutide commercial supply start | From freedom-to-operate perspective, if everything goes to plan | Q4 (calendar) |
| No additional GLP DDC customer onboarding | To avoid capacity clash with existing relationships | Until further notice |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹426 crore, +22% YoY |
| Full-year revenue | ₹1,444.9 crore, +30% YoY |
| EBITDA | ₹182.5 crore, +79% YoY |
| Full-year EBITDA | ₹466.5 crore, more than twice FY24 |
| EBITDA margin | 43% |
| PAT | ₹99.2 crore, versus a loss in prior year |
| Full-year adjusted PAT | ₹93.6 crore, excluding one-timers |
| Annualized Q4 EPS | ₹48.9, fully diluted, excluding exceptional items and scheme-related intangibles |
| Full-year EPS | ₹21.4, fully diluted, excluding exceptional items and scheme-related intangibles |
| Full-year ROCE | 22.9% |
| Q4 annualized ROCE | 40.9% |
| Net debt | ₹470.7 crore, net of cash and cash equivalents |
| Interest cost | ₹27.8 crore, down 20% QoQ |
| Fixed asset turns | 1.9, anticipated to remain higher than 2 |
| Customer logo count | 70+ |
| DDC projects | ~50, in various stages of execution |
| DDC customers | 20+ |
| Rated capacity expansion | from 4 crore to a little over 9 crore, as early as December |
| Capex plan | ~$100 million, over the next couple of years |
| FY25–FY28 revenue growth CAGR guidance | 30% |
| Steady-state EBITDA margin guidance | 40% |
| FY28 revenue target | $400 million |
| FY28 EBITDA margin target | 38% to 40% |
| Debt-to-EBITDA target | below 1.5, over the medium term |
| Net-debt-free target | next 2 to 3 years |